1732 related articles for article (PubMed ID: 8218934)
1. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
Urano K; Habu S; Nishimura T
Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
[TBL] [Abstract][Full Text] [Related]
2. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
Nakajima I; Okuno K; Ohnishi H; Shilayama Y; Nakamura T; Hirohata T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
[TBL] [Abstract][Full Text] [Related]
3. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
Yang SC; Fry KD; Grimm EA; Roth JA
Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour.
Neville ME; Pezzella KM
Cytokine; 1994 May; 6(3):310-7. PubMed ID: 8054488
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
6. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
8. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
9. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
10. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
12. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
13. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
14. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
Jelinek DF; Lipsky PE
J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
[TBL] [Abstract][Full Text] [Related]
17. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.
Kawase I; Komuta K; Shirasaka T; Hara H; Tanio Y; Watanabe M; Saito S; Ikeda T; Masuno T; Kishimoto S
Jpn J Cancer Res; 1989 Nov; 80(11):1089-97. PubMed ID: 2514171
[TBL] [Abstract][Full Text] [Related]
18. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.
Mandrup-Poulsen T; Bendtzen K; Dinarello CA; Nerup J
J Immunol; 1987 Dec; 139(12):4077-82. PubMed ID: 3320203
[TBL] [Abstract][Full Text] [Related]
19. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors.
Noguchi K; Inagawa H; Tsuji Y; Morikawa A; Mizuno D; Soma G
J Immunother (1991); 1991 Apr; 10(2):105-11. PubMed ID: 2043590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]